GleamWall
中文EN

SILO Silo Pharma, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1514183 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-50.0%
TTM net income YoY26.7%
TTM EPS YoY159.8%
Revenue 3-yr CAGR-20.6%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-12,534.1%
Net margin-10,319.0%
FCF margin—
EBITDA margin—

Returns

ROE-55.3%
ROA-49.0%
ROIC (approx.)-207.1%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets4.0%
Debt / equity0.00x
Current ratio24.43x
Interest coverage-112.82x

Cash quality & payout

Operating cash flow / net income0.80x
Accruals ratio-9.6%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$72,102$72,102
Cost of revenue$44,295$5,838
Gross profit$27,807$66,264
R&D expense$2.16M$2.37M
Operating income-$4.28M-$4.71M
Interest expense$37,302$5,084
Pretax income-$4.23M-$4.39M
Net income-$4.23M-$4.39M
EPS (basic)-0.50-1.19
EPS (diluted)-0.50-1.19
Weighted avg. shares (diluted)8.38M3.68M
Balance sheet
Cash & equivalents$4.75M$3.91M
Short-term investments$2.11M$3.17M
Current assets$7.39M$7.11M
Intangibles$217,375$241,215
Total assets$7.61M$7.41M
Current liabilities$650,183$1.66M
Total liabilities$1.30M$2.38M
Shareholders' equity$6.31M$5.03M
Shares outstanding887,8864.48M
Cash flow statement
Operating cash flow-$4.66M-$3.83M
Investing cash flow$644,021$973,777
Financing cash flow$4.86M$3.24M
Stock-based compensation$117,021$0

Free plan shows the latest 2 periods; Pro shows all 12 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.